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UPDATE
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High HIV Incidence among
Male Injection Drug Users in Delhi, India

India has a large injection drug user (IDU) population estimated at 177,000. The overall national HIV prevalence
is around 7.2 percent in this group, which is the highest
among all key populations in the country including antenatal care attendees, female sex workers, men who have
sex with men and patients at sexually transmitted infection (STI) clinics.1, 2 While there is information available
on HIV prevalence from different regions of the country,
there is limited HIV incidence data among IDUs in India.

line, they have been excluded from the analysis. Only HIV
negative male IDUs have been included in the incidence
analysis. Trained research interviewers administered a
close-ended questionnaire in Hindi to collect data on
socio demographic characteristics, injecting practices,
sexual behaviours, knowledge of HIV and utilization of
harm reduction services.

In collaboration with Arise—Enhancing HIV Prevention
Programs for At-Risk Populations, the Population Council
initiated a prospective cohort study at five centers operated by Sahara Centre for Rehabilitation and Residential
Care (SAHARA) in Delhi to examine HIV incidence and
behavior change pre-introduction (control phase) and
post-introduction (intervention phase) of HIV prevention
services among IDUs. The study entails three rounds
of data collection: baseline, follow-up visit 1 (FV1) and
follow-up visit 2 (FV2) at the end of the study. Here we
report the HIV incidence and correlates of incident HIV
infections in the HIV-negative male IDUs cohort during the
control phase.

HIV serostatus at baseline was determined using NACO
guidelines using rapid tests: HIV-negative status was
based on a single highly sensitive rapid test and a positive result on two additional confirmatory rapid tests.
At FV1, all HIV-negative male IDUs were tested using a
fourth generation Antigen-Antibody test followed by a
confirmatory Western Blot Assay. For participants who
tested positive on Western Blot at FV1, their HIV-negative
status at baseline was confirmed to rule out any window
period HIV infection at baseline using a fourth generation
Antigen-Antibody test on a stored serum sample. For
participants with a negative or indeterminate result on
the Western blot test at FV1, a plasma HIV PCR RNA test
was conducted on the FV1 plasma sample to identify any
window period infection at FV1.

Study Methodology

Analysis

The baseline assessment was undertaken from May to
October 2011 at five sites operated by SAHARA within
Delhi. Participants were recruited through peer-referral
(26.3 percent), targeted outreach by outreach workers
(53.6 percent), and walk-ins (20.1 percent). Eligibility criteria included being at least 18 years of age, residing in
and around Delhi, and having injected drugs at least once
in the last three months. A total of 3,792 males, including
10 transgender, were recruited into the study. As very few
female IDUs (n=26) were recruited in the study at base-

HIV incidence rate was calculated over the control phase
(date of FV1–date of baseline) by dividing the number
of new infections by the total person-years of follow-up.
Sero-conversion date was taken to be the date of HIV test
at FV1 visit. Bivariate and multivariate analyses using Cox
proportional hazard ratios were conducted to determine
behavioral factors associated with incident HIV infections
after controlling for age, education, marital status and
accommodation.

This material was produced under Arise—Enhancing HIV Prevention for At-Risk Populations. Arise implements innovative HIV prevention initiatives for
vulnerable communities, with a focus on determining cost-effectiveness through rigorous evaluations.

Study Population

Of the 2,790 eligible male HIV-negative IDUs recruited at
baseline, 1,880 (67.4 percent) HIV-negative male IDUs
returned for their FV1 visit. Among those, HIV testing was
conducted for 1,806 (96 percent) and behavioral survey
completed. The median follow-up time among participants was 9.7 months (IQR: 8.1, 11.1). The median age
was 28 years [IQR: 23, 38]. About one-half (47.7 percent)
were illiterate, and 53.5 percent were never married.
IDUs were living with family or relatives (43.9 percent), living on the street or slum (39.5 percent) or living in rented
home or were a paying guest (16.6 percent).

Key Findings
High HIV incidence among male IDUs in Delhi

A total of 112 new HIV infections occurred over a cumulative 1,443.76 person-years of follow-up resulting in an incidence rate of 7.76 new infections per 100 person-years
(95 percent CI: 6.45–9.34).

Risky injection practices were common among
newly HIV-infected IDUs

Among the 112 newly HIV-infected participants, 74
percent (n=83) reported risky injection behaviorsi in the
last month preceding FV1. These high-risk practices in
conjunction with the high HIV prevalence are fueling the
HIV incidence.

Risky injection practices associated with higher
risk of HIV

On multivariate analysis, after controlling for age, education, marital status and accommodation, risky injection
behaviors (Hazard risk ratio [HRR] 2.76; 95 percent CI
1.54–4.93), injecting smack/brown sugar (HRR: 2.43; 95
percent CI: 1.53–3.87) were significantly associated with
a higher risk of new infections. Injection with tranquilizers
were associated with a lower risk of new infections (HRR:
0.53; 95 percent CI: 0.32–0.86; p=0.01).

i
A 5-item ‘Risky Injection Behavior’ index was derived from various
injection practices in the last one month: (i) Using needles or syringes
previously used by someone else; (ii) Back/ front loading/splitting drugs
(iii) Shared vial, cooker, container, cotton, filter or water; (iv) Receiving
an injection with syringe filled by someone else; and (v) Drawing up
drugs from a common container.

Sex partners at high risk of HIV infection

Although sexual activity was not associated with risk of
incident infections, of the 112 participants with new infections, 20.5 percent reported unsafe sex with a female
partner in the three months preceding the survey.

Conclusion and Program Implications

HIV transmission risk remains high among IDUs in Delhi
despite targeted prevention interventions for this population. The incidence of 7.76 per 100 person-years among
male IDUs in Delhi is higher than other cities with established HIV epidemic among IDUs such as St. Petersburg,
Russia (4.5 per 100 person-years) and Bangkok, Thailand
(5.8 per 100 person-years), but is comparable to the
incidence among IDUs in Xinjiang, China (8.8 per 100
person-years).3–5
Despite the widespread availability of free sterile needles
and syringes from needle exchange programs (NSEP) and
targeted interventions with harm reduction messages,
HIV risk is primarily associated with risky drug injection
practices. Only a small proportion of our cohort reported
accessing NSEP services and only 10 percent reported accessing opioid substitution therapy in the month
preceding the survey. Therefore, targeted intervention
programs must find ways to: i) increase regular access
to harm reduction services; and ii) that use of services
actually translates to changed behaviors.
This study also demonstrates that a large number of IDUs
can be enrolled into a prevention study with reasonable
rate of follow-up. Thus, this population should be considered for future HIV prevention trials.
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